Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Our Plans

Compare everything

See all plans, pricing and what each product includes side by side.

Plans & Subscriptions

Explore

Analyst Notes

Stocks – Q : Quality | V : Valuation | PT : Price Trend
Funds – P : Performance | Q : Quality

Top Pharma Companies in India by Market Cap

BSE Sensex 76941.61
105.83 (0.14%)

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
31	Acutaas Chemicals Ltd.	Q V+ PT	27,579 Small Cap	3,109.85 (-7.68%)	69.39	15.81	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
32	CORONA Remedies Ltd.	Q V+ PT	12,807 Small Cap	2,092.45 (-0.08%)	69.28	17.17	19.49	18.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
33	Neuland Laboratories Ltd.	Q V+ PT	24,345 Small Cap	18,887 (-0.47%)	67.05	13.05	16.64	37.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
34	Innova Captab Ltd.	Q V PT	5,527 Small Cap	966.05 (0.02%)	66.04	6.23	25.90	14.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
35	Viyash Scientific Ltd.	Q V PT	11,352 Small Cap	256.15 (-1.42%)	64.03	4.2	20.23	2.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
36	Metropolis Healthcare Ltd.	Q V PT	11,981 Small Cap	592.35 (2.53%)	63.05	7.92	9.22	2.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
37	Gufic Biosciences Ltd.	Q V PT	3,826 Small Cap	381.95 (0.10%)	60.59	5.76	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
38	Rainbow Childrens Medicare Ltd.	Q V PT	15,076 Small Cap	1,471 (-0.90%)	60.3	8.95	20.26	35.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
39	Dr. Lal Pathlabs Ltd.	Q V PT	30,607 Small Cap	1,813.55 (-0.67%)	56.18	11.9	12.18	13.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
40	Jupiter Life Line Hospitals Ltd.	Q V PT	10,728 Small Cap	322.10 (-1.57%)	56.06	6.67	21.03	54.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
41	Syngene International Ltd.	Q V+ PT	16,710 Small Cap	408.40 (-1.34%)	54.8	3.58	9.45	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
42	Thyrocare Technologies Ltd.	Q V+ PT	9,287 Small Cap	592.20 (1.49%)	52.68	14.76	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
43	Strides Pharma Science Ltd.	Q V+ PT	9,623 Small Cap	1,055.20 (1.07%)	52.4	2.93	3.25	-0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
44	Narayana Hrudayalaya Ltd.	Q V PT	41,974 Mid Cap	2,070.80 (0.82%)	52.1	9.25	25.04	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
45	Granules India Ltd.	Q V+ PT	20,878 Small Cap	843 (0.05%)	51.82	5.09	2.07	-5.88	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
46	Mankind Pharma Ltd.	Q V PT	1,05,357 Mid Cap	2,586.05 (1.37%)	51.71	6.44	13.54	13.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
47	Poly Medicure Ltd.	Q V PT	17,025 Small Cap	1,666.30 (-0.79%)	50.67	5.58	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
48	Bliss GVS Pharma Ltd.	Q V+ PT	4,898 Small Cap	450.60 (-2.26%)	50.56	4.28	9.41	4.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
49	Concord Biotech Ltd.	Q V PT	13,150 Small Cap	1,252.25 (-0.38%)	50.4	6.52	11.33	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
50	Shilpa Medicare Ltd.	Q V+ PT	12,144 Small Cap	605.90 (-2.42%)	49.91	4.69	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
51	Emcure Pharmaceuticals Ltd.	Q V+ PT	36,490 Small Cap	1,945.55 (1.13%)	49.78	9.83	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
52	Morepen Laboratories Ltd.	Q V PT	3,101 Small Cap	55.70 (-1.57%)	46.94	2.5	14.44	19.03	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
53	Bajaj Healthcare Ltd.	Q V PT	1,078 Small Cap	319.95 (-0.05%)	46.8	1.97	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
54	Shree Ganesh Remedies Ltd.	Q V PT	822 Small Cap	633.75 (-1.04%)	46.26	5.04	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
55	Glenmark Pharmaceuticals Ltd.	Q V+ PT	61,928 Mid Cap	2,198.30 (0.18%)	45.47	5.89	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
56	Blue Jet Healthcare Ltd.	Q V PT	10,906 Small Cap	577 (0.14%)	44.01	5.05	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
57	Artemis Medicare Services Ltd.	Q V PT	4,408 Small Cap	278.40 (-0.02%)	42.61	5.07	21.41	79.02	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
58	RPG Life Sciences Ltd.	Q V+ PT	4,827 Small Cap	2,882.80 (-1.22%)	41.91	7.97	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
59	Kwality Pharmaceuticals Ltd.	Q V+ PT	2,815 Small Cap	2,651 (-2.29%)	41.8	8.47	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
60	SMS Pharmaceuticals Ltd.	Q V+ PT	3,662 Small Cap	382.60 (-2.15%)	41.8	4.55	13.70	14.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.25	3.23%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	592.35	2.53%
Fabtech Technologies	152.35	2.49%
Laurus Labs	1,745.85	1.84%

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,109.85	-7.68%
Senores Pharmaceutic	1,318.70	-6.57%
Suven Life Sciences	298.90	-4.11%
Wanbury	318.45	-3.85%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

SMS Pharmaceuticals informs about board meeting

SMS Pharmaceuticals has informed that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026, inter alia, to consider and approve Un-audited Financial Results of the Company for the first quarter ended on June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Dr. Lal Pathlabs - Quaterly Results

The company witnessed a 19.31% growth in the revenue at Rs. 7644.00 millions for the quarter ended June 2026 as compared to Rs. 6407.00 millions during the year-ago period.The company has announced a 28.31% increase in its profits to Rs . 1659.00 millions for the quarter ended June 2026 compared to Rs. 1293.00 millions in the corresponding quarter in the previous year.Operating Profit saw a handsome growth to 2684.00 millions from 2097.00 millions in the quarter ended June 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	7644.00	6407.00	19.31	7644.00	6407.00	19.31	26476.00	23516.00	12.59
Other Income	299.00	263.00	13.69	299.00	263.00	13.69	1127.00	1115.00	1.08
PBIDT	2684.00	2097.00	27.99	2684.00	2097.00	27.99	8664.00	7770.00	11.51
Interest	61.00	45.00	35.56	61.00	45.00	35.56	220.00	215.00	2.33
PBDT	2623.00	2052.00	27.83	2623.00	2052.00	27.83	8143.00	7555.00	7.78
Depreciation	400.00	328.00	21.95	400.00	328.00	21.95	1541.00	1342.00	14.83
PBT	2223.00	1724.00	28.94	2223.00	1724.00	28.94	6602.00	6213.00	6.26
TAX	564.00	431.00	30.86	564.00	431.00	30.86	1520.00	1240.00	22.58
Deferred Tax	-9.00	22.00	-140.91	-9.00	22.00	-140.91	14.00	-393.00	-103.56
PAT	1659.00	1293.00	28.31	1659.00	1293.00	28.31	5082.00	4973.00	2.19
Equity	1676.00	838.00	100.00	1676.00	838.00	100.00	1676.00	836.00	100.48
PBIDTM(%)	35.11	32.73	7.28	35.11	32.73	7.28	32.72	33.04	-0.96

Jul, 2026

Acutaas Chemicals - Quaterly Results

The Turnover for the quarter ended June 2026 of Rs. 3224.09 millions increase by 56.53% from Rs. 2059.71 millions.Net profit for the quarter ended June 2026 increased significantly by 70.00% to Rs. 758.96 millions from Rs. 446.46 millions.Operating profit for the quarter ended June 2026 rose to 1141.53 millions as compared to 670.09 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3224.09	2059.71	56.53	3224.09	2059.71	56.53	13237.92	9898.35	33.74
Other Income	44.76	160.20	-72.06	44.76	160.20	-72.06	458.78	183.36	150.21
PBIDT	1141.53	670.09	70.35	1141.53	670.09	70.35	5288.83	2434.78	117.22
Interest	11.18	6.20	80.32	11.18	6.20	80.32	30.77	58.57	-47.46
PBDT	1130.35	663.89	70.26	1130.35	663.89	70.26	5258.06	2376.21	121.28
Depreciation	90.20	74.62	20.88	90.20	74.62	20.88	330.32	240.45	37.38
PBT	1040.15	589.27	76.52	1040.15	589.27	76.52	4927.74	2135.76	130.73
TAX	281.19	142.81	96.90	281.19	142.81	96.90	1265.99	540.29	134.32
Deferred Tax	25.87	15.53	66.58	25.87	15.53	66.58	111.09	70.58	57.40
PAT	758.96	446.46	70.00	758.96	446.46	70.00	3661.75	1595.47	129.51
Equity	409.36	409.34	0.00	409.36	409.34	0.00	409.36	409.34	0.00
PBIDTM(%)	35.41	32.53	8.83	35.41	32.53	8.83	39.95	24.60	62.42

Jul, 2026

Thyrocare Tech. - Quaterly Results

The sales figure stood at Rs. 2256.60 millions for the June 2026 quarter. The mentioned figure indicates a growth of about 26.14% as compared to Rs. 1788.90 millions during the year-ago period.Good Net Profit growth of 39.17% reported above the corresponding previous quarter figure of Rs. 360.50 millions to Rs. 501.70 millioins.OP of the company witnessed a marginal growth to 791.20 millions from 604.80 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	2256.60	1788.90	26.14	2256.60	1788.90	26.14	7742.70	6331.00	22.30
Other Income	35.10	39.60	-11.36	35.10	39.60	-11.36	133.90	133.40	0.37
PBIDT	791.20	604.80	30.82	791.20	604.80	30.82	2697.20	2003.60	34.62
Interest	12.60	6.20	103.23	12.60	6.20	103.23	21.80	26.30	-17.11
PBDT	778.60	598.60	30.07	778.60	598.60	30.07	2615.70	1977.30	32.29
Depreciation	112.30	89.50	25.47	112.30	89.50	25.47	511.70	465.20	10.00
PBT	666.30	509.10	30.88	666.30	509.10	30.88	2104.00	1512.10	39.14
TAX	164.60	148.60	10.77	164.60	148.60	10.77	615.90	554.30	11.11
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	43.00	76.60	-43.86
PAT	501.70	360.50	39.17	501.70	360.50	39.17	1488.10	957.80	55.37
Equity	1591.70	529.90	200.38	1591.70	529.90	200.38	1591.70	529.90	200.38
PBIDTM(%)	35.06	33.81	3.71	35.06	33.81	3.71	34.84	31.65	10.07

Jul, 2026

Rainbow Children’s Medicare informs about ESG rating

Pursuant to Regulation 30 of the SEBI Listing Regulations read with Schedule III thereto and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Rainbow Children’s Medicare has informed that CRISIL ESG Rating & Analytics (‘CRISIL ESG’) has on a voluntary basis assessed the overall Environmental, Social and Governance (ESG) and has assigned an ESG rating of 61 and a Core ESG rating of 73, based on disclosures for FY 2025-26, on July 22, 2026. The ESG rating of 61 reflects an improvement from ‘Adequate’ to ‘Strong’ ESG rating assigned to the Company for FY 2024-25 and FY 2023-24. The Company has not engaged CRISIL ESG for ESG Ratings. CRISIL ESG has independently prepared the report based on data pertaining to FY 2025-26 for the Company available in public domain.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

SMS Pharmaceuticals informs about newspaper publication

Pursuant to Regulations 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has enclosed copies of the newspaper advertisement published on 22nd July, 2026, informing the shareholders about transfer of shares to Investor Education Protection Fund (IEPF) pertaining to the unpaid/ unclaimed dividend for the financial year 2018 -2019. The advertisement has been published in the following newspapers: Financial Express (in English language), Nava Telangana (in Telugu language). The newspaper advertisements are also made available on the website of the Company www.smspharma.com at Investors Section.

The above information is a part of company’s filings submitted to BSE.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Biocon Ltd.	71,063 Crore
2	Jubilant Pharmova Ltd.	15,582 Crore
3	Healthcare Global Enterprises Ltd.	10,110 Crore
4	Onesource Specialty Pharma Ltd.	19,375 Crore
5	Senores Pharmaceuticals Ltd.	6,500 Crore
6	Park Medi World Ltd.	12,060 Crore
7	Fortis Healthcare Ltd.	71,140 Crore
8	Aster DM Quality Care Ltd.	70,000 Crore
9	Wockhardt Ltd.	30,311 Crore
10	Rubicon Research Ltd.	25,860 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,932	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,629	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,294	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,932	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,551	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,294	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,586	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,145	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,983	4,73,509	41.25	5.67	23.65	14.41

About MoneyWorks4Me

*Color code for outperformance consistency

*Number is average 3 year rolling returns

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

SMS Pharmaceuticals informs about board meeting

Dr. Lal Pathlabs - Quaterly Results

Acutaas Chemicals - Quaterly Results

Thyrocare Tech. - Quaterly Results

Rainbow Children’s Medicare informs about ESG rating

SMS Pharmaceuticals informs about newspaper publication

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

SMS Pharmaceuticals informs about board meeting

Dr. Lal Pathlabs - Quaterly Results

Acutaas Chemicals - Quaterly Results

Thyrocare Tech. - Quaterly Results

Rainbow Children’s Medicare informs about ESG rating

SMS Pharmaceuticals informs about newspaper publication

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.